GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Capex-to-Operating-Cash-Flow

Hualan Biological Engineering (SZSE:002007) Capex-to-Operating-Cash-Flow : 2.20 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Hualan Biological Engineering's Capital Expenditure for the three months ended in Mar. 2024 was ¥-110.36 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was ¥50.19 Mil.

Hence, Hualan Biological Engineering's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 2.20.


Hualan Biological Engineering Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Hualan Biological Engineering's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Capex-to-Operating-Cash-Flow Chart

Hualan Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.47 0.57 0.41 0.56

Hualan Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.47 - 0.34 2.20

Competitive Comparison of Hualan Biological Engineering's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Hualan Biological Engineering's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's Capex-to-Operating-Cash-Flow falls into.



Hualan Biological Engineering Capex-to-Operating-Cash-Flow Calculation

Hualan Biological Engineering's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-753.411) / 1345.839
=0.56

Hualan Biological Engineering's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-110.356) / 50.186
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Engineering  (SZSE:002007) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Hualan Biological Engineering Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering (SZSE:002007) Business Description

Traded in Other Exchanges
N/A
Address
No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
An Kang Directors, executives
Pan Ruo Wen Executives
An Wen Qi Executives
Wang Qi Ping Directors, executives
Fan Bei Directors, executives
Ma Xiao Wei Executives
Xie Jun Min Directors, executives
Zhang Bao Xian Executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors
Sun Zhen Guo Supervisors
Chen Lei Shan Supervisors
Yang Bao Ping Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines